메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection

BEIJING and GOTHENBURG, Sweden, Oct. 24, 2025 -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of Hepatitis D Virus (HDV) infection. The EMA's ODD is assigned to investigational therapies of life-threatening or chronically debilitating rare diseases that affect no more than five in 10,000 individuals in the European Union. The ODD status provides significant regulatory and commercial incentives, thus enabling
- 김갑성 기자
- 2025-10-24 18:12
AXA Garners Seven Awards at The Hong Kong Insurance Awards 2025

HONG KONG, Oct. 24, 2025 -- AXA Hong Kong and Macau ("AXA") received seven accolades at The Hong Kong Insurance Awards 2025, including three winners and four top 3. The awards spanned key areas such as strategic partnerships, product innovation, AI and analytics, digital transformation, ESG and sustainability, corporate social responsibility, and the demonstrated professionalism and industry expertise of our financial consultants. This recognition underscores AXA's continued leadership in innovation and customer-centric excellence across products and services. It also reflects the C
- 김갑성 기자
- 2025-10-24 17:55
Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore

The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinics in October 2025 for individuals 6 months of age and older. SINGAPORE, Oct. 24, 2025 -- Pfizer Singapore and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Health Sciences Authority has approved the companies' LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in individuals 6 months of age and older, according to official recommendations*. This marks Singapore a
- 김갑성 기자
- 2025-10-24 17:33
Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website

SHANGHAI, Oct. 24, 2025 -- At 15:00 Beijing Time (09:00 am Berlin Time) on October 20, the "Global Launch Event for Iza-bren (EGFR×HER3 Bispecific ADC) Nasopharyngeal Carcinoma BL-B01D1-303 Research Results" was held at the venue of the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin. eChinaHealth held a forum on progress of nasopharyngeal carcinoma, and Biokin Pharma participated in sharing the research results and reported the Iza bren BL-B01D1-303 research report. The Launch Event focused on the BL-B01D1-303 study (hereinafter: 303 Study) led by
- 김갑성 기자
- 2025-10-24 16:40
Gushengtang TCM and 1doc Form Strategic Partnership to Establish Singapore's Integrated TCM Service Model

SINGAPORE, Oct. 24, 2025 -- Gushengtang TCM officially launched its "Master TCM AI" system at GovWare 2025 on October 22. The launch coincides with a strategic partnership with 1doc and a signed agreement with August Global Partners (AGP) for strategic investment, supporting the shift toward evidence-based integrative medicine. Gushengtang's senior leadership, including Founder and Chairman Tu Zhiliang, Group Vice President Zheng Xiang and Vice President Vicky Liem, Chief Technology Officer Hu Zhongkai, and Southeast Asia Vice General Manager Shen Lin, were present at
- 김갑성 기자
- 2025-10-24 15:08
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/αvβ6 Bispecfic ADC JSKN022

SUZHOU, China, Oct. 24, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed at Sun Yat-sen University Cancer Center in the phase I clinical study (Study ID: JSKN022-101) of JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and integrin αvβ6, for the treatment of advanced malignant solid tumors. JSKN022 is the Company's fourth ADC candidate entering clinical development, as well as the world's first PD-L1/αvβ6 bispecific ADC to advance into clinical trials. JSKN022 innovatively
- 김갑성 기자
- 2025-10-24 12:56
HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity

[ 메디채널 김갑성 기자 ] FACO 2025 presentation highlights HCB101's favorable safety, strong receptor occupancy, and confirmed responses in patients with advanced cancers. TAIPEI, SHANGHAI, and SAN FRANCISCO, Oct. 24, 2025 -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies, today presented new results from its ongoing Phase 1 study of HCB101, a novel SIRPα-engineered Fc fusion protein, at the 13th International Conference of the Federation of Asian Clinical Oncology (FACO 2025), held October 24-25, 2025, in Shanghai, Mainla
- 김갑성 기자
- 2025-10-24 07:30
World Psoriasis Day 2025: IFPA Calls to Stop the Domino Effect of Psoriasis

IFPA urges recognition of the close link between psoriasis and mental health — and action to prevent its devastating ripple effects. STOCKHOLM, Oct. 24, 2025 -- Every year on October 29, the global community marks World Psoriasis Day, raising awareness and standing in solidarity with more than 60 million people living with psoriatic disease worldwide. This year, IFPA (the International Federation of Psoriasis Associations) launches a global campaign "Stop the Domino Effect". IFPA's "Stop the Domino Effect" is urging policymakers, healthcare pr
- 김갑성 기자
- 2025-10-24 00:13
A New Era in Cervical Cancer Elimination: INNOVAX Presents Global Progress with HPV 9-Valent Vaccine on IPVS 2025 Opening Day

BANGKOK, Thailand, Oct. 23, 2025 -- Xiamen Innovax Biotech Co., Ltd. ("INNOVAX") participated in the 37th International Papillomavirus Society (IPVS) Conference, and hosted a dedicated symposium titled "A New Era of HPV Vaccines: The Efforts from Developing Country Manufacturers for Global Cervical Cancer Elimination" that stimulated significant discussion among attending global experts. Under the theme "Together Against HPV," Innovax also welcomed visitors to Booth #09, engaging with scholars and potential partners. The symp
- 김갑성 기자
- 2025-10-23 23:24
Avaz Joins the PRC-Saltillo Community, Expanding Global AAC Access and Multilingual Innovation

SINGAPORE, Oct. 23, 2025 -- PRC-Saltillo, the parent company of PRC Saltillo Singapore, and a global leader in augmentative and alternative communication (AAC), is proud to announce that Avaz, known for its multilingual, design-forward AAC app, is now a wholly owned subsidiary of PRC-Saltillo. This strategic acquisition marks a significant milestone in PRC-Saltillo's mission to expand access to AAC solutions worldwide. Expanded AAC Portfolio: Avaz's app joins PRC-Saltillo's trusted suite of AAC solutions—including TouchChat®, LAMP Words for Life®, Dialogue® AAC,
- 김장윤(JASON KIM) 기자
- 2025-10-23 23:00

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-11-04_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 04일 14시 40분